Abstract
Purpose Breast density is associated with risk of developing cancer and can be automatically estimated, using deep learning models, from digital mammograms. Our aim is to estimate the capacity and reliability of such models to estimate density from low dose mammograms taken to enable risk estimates for younger women.
Methods We trained deep learning models on standard and simulated low dose mammograms. The models were then tested on a mammography data-set with paired standard and low-dose image. The effect of different factors (including age, density and dose ratio) on the differences between predictions on standard and low dose are analysed. Methods to improve performance are assessed and factors that reduce model quality are demonstrated.
Results We showed that whilst many factors have no significant effect on the quality of low dose density prediction both density and breast area have an impact. For example correlation between density predictions on low and standard dose images of breasts with the largest breast area is 0.985 (0.949-0.995) while with the smallest is 0.882 (0.697-0.961). We also demonstrated that averaging across CC-MLO images and across repeatedly trained models can improve predictive performance.
Conclusion Low dose mammography can be used to produce density and risk estimates that are comparable to standard dose images. Averaging across CC-MLO and across model predictions should improve this performance. Model quality is reduced when making predictions on denser and smaller breasts. Code is available at: https://github.com/stevensquires/
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ISRCTN55983830
Funding Statement
The ALDRAM study was funded by the Medical Research Council (UK).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval for the PROCAS study was through the North Manchester Research Ethics Committee (09/H1008/81). Informed consent was obtained from all participants on entry to the PROCAS study. Ethics approval for the ALDRAM study was granted on 12/02/2019 by the North West - Preston Research Ethics Committee (Barlow House, 3rd Floor, 4 Minshull Street, Manchester M1 3DZ; +44 (0)2071048234; preston.rec{at}hra.nhs.uk), ref: 19/NW/0037
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data is not available to researchers outside of the University of Manchester.
